Healthcare / Drug Manufacturers - GeneralBSE
$196.05
+12.60 (+6.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-133.6M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.5B
P/E
36.9x
↑EV/EBITDA
17.6x
↑ROE
4.9%
↑Gross Margin
35.6%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+7.5%
FCF CAGR
—
FCF margin
-0.1%
FCF / Net income
-0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.81B · net income $257.3M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.81B | $6.81B | $6.30B | $6.15B | $5.48B |
| Net Income | $257.3M | $257.3M | $385.5M | $509.6M | $272.3M |
| EBITDA | $623.0M | $623.0M | $768.8M | $868.2M | $532.8M |
| EPS | 5.33 | 5.33 | 7.99 | 10.55 | 5.65 |
| Gross Margin | 35.6% | 35.6% | 35.7% | 34.6% | 31.8% |
| Operating Margin | 8.9% | 8.9% | 9.1% | 10.0% | 8.3% |
| Net Margin | 3.8% | 3.8% | 6.1% | 8.3% | 5.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.29 | 0.20 | 0.17 |
| Current Ratio | 1.51 | 1.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-169.8M | $-133.6M | $-270.2M |
| Returns | |||||
| ROE | 4.9% | 4.9% | 7.4% | 10.4% | 6.2% |
| Valuation | |||||
| P/E | 36.85 | 36.85 | 23.09 | 26.45 | 21.65 |
| EV/EBITDA | 17.63 | 17.63 | 13.25 | 16.58 | 12.34 |
| P/B | 1.78 | 1.78 | 1.72 | 2.74 | 1.34 |
| Growth & Yield | |||||
| Revenue Growth | 8.2% | 8.2% | 2.4% | 12.1% | — |
| EPS Growth | -33.3% | -33.3% | -24.3% | 86.7% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
48.3%
EPS terminal req.
$17.40
Spread vs growth
-81.6%
5Y implied EPS CAGR
31.6%
EPS terminal req.
$21.05
Spread vs growth
-64.9%
10Y implied EPS CAGR
20.3%
EPS terminal req.
$33.90
Spread vs growth
-53.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.1%
Start / end P/E
23.8x → 38.7x
EPS bridge
7.99 → 5.33
Residual
-20.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.